CorMedix
CRMD
33 hedge funds and large institutions have $4.38M invested in CorMedix in 2017 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 9 reducing their positions, and 4 closing their positions.
0% more funds holding
Funds holding: 33 → 33 (0)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
2.16% less ownership
Funds ownership: 4.99% → 2.83% (-2.2%)
31% less capital invested
Capital invested by funds: $6.34M → $4.38M (-$1.96M)
44% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 9
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $67K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$41.5K |
| 2 |
Franklin Resources
San Mateo,
California
|
+$21.9K |
| 3 |
NCCM
Nine Chapters Capital Management
Short Hills,
New Jersey
|
+$17.6K |
| 4 |
PCM
Prelude Capital Management
New York
|
+$6.22K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$4.97K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$1.49M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$886K |
| 3 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$339K |
| 4 |
GLRA
Gerald L. Ray & Associates
Dallas,
Texas
|
-$29K |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$19.6K |
CRMD Hedge Fund Activity: Q3 2017 in Review
33 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in CorMedix (CRMD) for Q3 2017, worth a combined $4.38M — down 31% from $6.34M a quarter earlier.
Fund positioning in CRMD was balanced in Q3 2017: 4 funds opened new positions, 4 closed out, 5 added to existing stakes and 9 trimmed.
The largest buyer was Virtu Financial, opening a new position worth an estimated $41.5K. The largest seller was Sabby Management, cutting an estimated $1.49M.
- 33 institutional investors held CorMedix (CRMD) as of Q3 2017, unchanged from Q2 2017.
- Funds reported $4.38M of CorMedix stock for Q3 2017, down 31% quarter-over-quarter.
- 4 funds opened new CorMedix positions in Q3 2017 and 4 closed out, a net change of 0 holders.
- The largest CorMedix buyer in Q3 2017 was Virtu Financial, an estimated $41.5K added.
- The largest CorMedix seller in Q3 2017 was Sabby Management, an estimated $1.49M sold.
Based on aggregated 13F filings for Q3 2017.